Testing a new pill vs. standard drug for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer (stage IV or some stage III) that cannot be removed by surgery or treated with radiation.
- Your cancer has a change called ALK-fusion (confirmed by a tumor or blood test).
- You have not had any previous cancer treatment for NSCLC (some exceptions for a single chemotherapy or prior adjuvant therapy).
- You have at least one tumor that can be measured on scans and is not in your brain.
- You are generally well enough to be up and about (ECOG 0-2) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests TQB2450 (a new cancer medicine) added to chemotherapy, or along with an oral medicine called anlotinib, for stage II–IIIB non-small cell lung cancer. It may help shrink tumors and improve outcomes in people who are getting curative surgery and have not had prior cancer drug treatment.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.